SCHEMBL7634352

SCHEMBL7634352

C#CCOc1ccc(C(=O)C=Cc2ccc(C#N)cc2)c(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 1/20 0.61
MAOB P27338 14/20 0.54
APP P05067 3/20 0.53
MEN1 O00255 2/20 0.53
LMNA P02545 2/20 0.53
CYP3A4 P08684 2/20 0.53
MAPT P10636 2/20 0.53
MAPK1 P28482 2/20 0.53
KMT2A Q03164 2/20 0.53
ABCG2 Q9UNQ0 2/20 0.53
CYP2C19 P33261 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MAOA P21397 1/20 0.53
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
BCHE P06276 1/20 0.51
ACHE P22303 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30383216 1.00 P4HB (0.61) P4HBMAOBAPPMEN1LMNA
SCHEMBL25195734 0.90 CYP3A4 (0.62) P4HBMAOBAPPMEN1LMNA
SCHEMBL7637445 0.86 MAOB (0.66) MAOBAPPMEN1LMNACYP3A4
SCHEMBL25210434 0.86 MAOB (0.66) MAOBAPPMEN1LMNACYP3A4
SCHEMBL30383778 0.86 MAOB (0.66) MAOBAPPMEN1LMNACYP3A4
SCHEMBL30383346 0.82 GUSB (0.55) MAOBAPPMEN1LMNACYP3A4
SCHEMBL25191038 0.82 GUSB (0.55) MAOBAPPMEN1LMNACYP3A4
SCHEMBL16375373 0.81 MAOB (0.64) MAOBAPPMEN1CYP3A4MAPT
SCHEMBL25203771 0.79 ABCG2 (0.55) MAOBAPPMEN1LMNACYP3A4
SCHEMBL31233091 0.79 ABCG2 (0.55) MAOBAPPMEN1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6423740-B1 ANTICARCINOGENIC AGENTS INDENA S.P.A. (IT) 2002-07-23 US claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-6423740-B1 ANTICARCINOGENIC AGENTS INDENA S.P.A. (IT) 2002-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B P4HB 552/4885MAOB 1004/4885APP 794/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 P4HB 469/4885MAOB 2435/4885APP 1340/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 P4HB 469/4885MAOB 2435/4885APP 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.